For this reason, we designed an anti-melanoma paradigm that employed the down-regulation of TGF-β1 in combination with the injection of miR200c agomir to enhance the antitumor effect of the B16F10/GPI-IL-21 vaccine on the B16F10 melanoma bearing mice. This evidence concerns the gene TGFB1 and melanoma.